Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

Evolving mCRPC treatment landscape in 2023

Xofigo Header Image

Description

The field of prostate cancer treatment is undergoing rapid evolution, with a noticeable shift towards earlier administration of therapies in the treatment pathway. These advancements have resulted in substantial changes in the approach to treating patients with metastatic castration-resistant prostate cancer (mCRPC).

In this on-demand webinar, Professor Joe O'Sullivan provides valuable insights into the positioning of Radium-223 within the treatment pathway and offers recommendations for optimising the sequencing of available treatments. Following Professor O'Sullivan, Dr. Matt Aldridge offers an overview of how to establish and enhance a Radium-223 service, drawing from his experience at Maidstone and Tunbridge Wells NHS Trust.

Interested in learning more? Watch the video below.

This promotional webinar was organised and funded by Bayer plc.

Xofigo▼ Prescribing Information

Speakers
    • Professor Joe Sullivan
      Professor Joe O'Sullivan

    Professor Joe O'Sullivan, a distinguished oncologist specialising in prostate cancer, holds the position of Professor of Radiation Oncology at Queen's University Belfast. His fervor lies in the care of prostate cancer patients, and he is deeply motivated to enhance outcomes across all facets of this illness while actively pioneering novel therapeutic approaches, particularly within the domains of External Beam Radiation Therapy and Bone-seeking radionuclide therapy.

    • Dr. Matt Aldridge
      Dr. Matt Aldridge

    Dr. Matthew Aldridge holds the esteemed position of Head of Nuclear Medicine Physics at the Maidstone and Tunbridge Wells NHS Trust. At the forefront of healthcare innovation, Dr. Aldridge leads a multidisciplinary team in overseeing the radium-223 service, a critical component of cancer care. With a profound dedication to improving patient outcomes, he continues to drive progress in the dynamic field of nuclear medicine, ensuring the highest standards of care and treatment for those in need.

BNMS 2024
Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
PP-XOF-GB-0598, January 2025

PP-XOF-GB-0505 | February 2024